Pharmaceutical
Health
Technology

Supernus Pharmaceuticals

$32.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.30 (-0.93%) Today
$0.00 (0.00%) As of 4:08 PM EDT after-hours

Why Robinhood?

You can buy or sell SUPN and other stocks, options, ETFs, and crypto commission-free!

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. Read More The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Employees
448
Headquarters
Rockville, Maryland
Founded
2005
Market Cap
1.68B
Price-Earnings Ratio
16.84
Dividend Yield
0.00
Average Volume
354.32K
High Today
$32.61
Low Today
$31.86
Open Price
$32.27
Volume
292.62K
52 Week High
$56.40
52 Week Low
$29.60

Collections

Pharmaceutical
Health
Technology
US
North America

SUPN Earnings

$0.27
$0.37
$0.47
$0.57
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.